Choice Institutional Equities has reiterated its positive stance on Glenmark Pharma following a major licensing deal between ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Glenmark Pharmaceuticals Ltd is quoting at Rs 2235, up 0.4% on the day as on 12:44 IST on the NSE. The stock is up 58.13% in last one year as compared to a 1.63% gain in NIFTY and a 8.9% gain in the ...

A warning letter is a serious communication from the USFDA that signifies a potential risk to public health or safety due to ...

In an official filing, the company stated that it does not anticipate the warning letter will disrupt supply chains or affect ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

With the stock currently trading at Rs 2,225.80, Glenmark Pharma has shown a positive movement of 2.05% in today's session.

Glenmark Pharmaceuticals share price surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

Motilal Oswal said the deal validates several aspects of Glenmark Pharma such as the strength of IGI's BEAT protein platform ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...